首页|胰高血糖素样肽-1受体激动剂类药物防治2型糖尿病视网膜病变的研究进展

胰高血糖素样肽-1受体激动剂类药物防治2型糖尿病视网膜病变的研究进展

扫码查看
糖尿病视网膜病变(DR)是2型糖尿病(T2DM)患者最常见的并发症之一,是近年来成年人致盲的主要眼部疾病。目前,胰高血糖素样肽-1受体激动剂(GLP-1RA)类药物因其优良的降糖、降脂、降压及心血管获益效果,已成为治疗糖尿病的主要药物。大量研究表明,GLP-1RA类药物在治疗糖尿病的同时,可以通过多种途径保护眼底微血管及神经,但也有研究发现,以司美格鲁肽为代表的GLP-1RA类药物可能会导致DR的进展。因此,对重度非增生型DR及增生型DR患者还是应当谨慎使用GLP-1RA类药物。不论T2DM患者是否合并DR,使用GLP-1RA类药物后应定期监测眼底视网膜情况,当DR发生和发展时及时采取应对措施。糖尿病患者使用GLP-1RA类药物的收益是有目共睹的,科学合理用药,防止DR的发生及进展,可以更好地造福DR患者。
Research progress in prevention and cure of glucagon-like peptide-1 receptor agonists-1 receptor agonists for diabetic retinopathy
Diabetic retinopathy(DR)is one of the most frequent complications of diabetes(T2DM),which is the main eye disease causing blindness in adults in recent years.At present,glucagon-like peptide-1 receptor agonists(GLP-1RA)have become the main drugs used in the treatment of diabetes due to its superior hypoglycemic,lipid-lowering,hypertensive and cardiovascular effects.A large number of studies have shown that GLP-1RA drugs can protect retinal microvascular and optic nerves in the treatment of diabetes through various ways,but some studies have found that GLP-1RA drugs represented by semaglutide may lead to the progress of DR.Therefore,GLP-1RA should be used cautiously for patients who with severe non-proliferative DR or proliferative DR.Regardless of whether T2DM patients are complicated with DR,the fundus retinal condition should be monitored regularly after the use of GLP-1RA drugs,and timely countermeasures should be taken when DR occurs and develops.The benefits of GLP-1RA used by diabetes patients are obvious to all,and scientific and rational drug use can prevent the occurrence and progress of DR,which can better benefit DR Patients.

Diabetic retinopathyGlucagon-like peptide-1 receptor agonistSemaglutideReview

吴涔怡、郦晓霞、沈雨、吴苗琴

展开 >

浙江中医药大学第二临床医学院,杭州 310053

杭州医学院附属人民医院 浙江省人民医院眼科,杭州 310014

糖尿病视网膜病变 胰高血糖素样肽-1受体激动剂 司美格鲁肽 综述

浙江省中医药科技计划

2023ZL241

2024

中华眼底病杂志
中华医学会

中华眼底病杂志

CSTPCD北大核心
影响因子:0.928
ISSN:1005-1015
年,卷(期):2024.40(2)
  • 61